SCHEMBL23391716

SCHEMBL23391716

CC(C)(C)OC(=O)n1c2ccncc2c2ccc(CCC=O)cc21

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 2/20 0.38
▸ GABRB3 P28472 2/20 0.38
▸ GABRA5 P31644 2/20 0.38
▸ GABRA1 P14867 1/20 0.36
▸ GABRA2 P47869 1/20 0.36
▸ GABRA6 Q16445 1/20 0.36
▸ NR1H2 P55055 9/20 0.35
▸ GPR119 Q8TDV5 5/20 0.35
▸ NR1H3 Q13133 3/20 0.35
▸ CHRM2 P08172 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ CYP17A1 P05093 1/20 0.33
▸ HDAC3 O15379 1/20 0.32
▸ HDAC2 Q92769 1/20 0.32
▸ HDAC6 Q9UBN7 1/20 0.32
▸ AAK1 Q2M2I8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23392066 0.86 NR1H2 (0.48) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL30256654 0.86 NR1H2 (0.48) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL30754584 0.86 NR1H2 (0.48) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL30256294 0.81 NR1H2 (0.36) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL16597821 0.79 GABRG2 (0.42) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL30544629 0.78 NR1H2 (0.37) GABRG2GABRB3GABRA5NR1H2NR1H3
SCHEMBL29773883 0.77 CHRM2 (0.49) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL18012185 0.74 GABRG2 (0.41) GABRG2GABRB3GABRA5GABRA1GABRA2
SCHEMBL20128913 0.73 FAAH (0.33) GPR119
SCHEMBL16597589 0.72 PRMT5 (0.42) GABRG2GABRB3GABRA5GABRA1GABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12622901-B2 Compounds for tau protein degradation DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-12 — — US disclosed
US-20240091213-A1 COMPOUNDS FOR TAU PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-03-21 — — US disclosed
EP-4310496-A2 COMPOUNDS FOR TAU PROTEIN DEGRADATION Dana-Farber Cancer Institute, Inc. (US) 2024-01-24 — — EP disclosed
US-20210154184-A1 COMPOUNDS FOR TAU PROTEIN DEGRADATION DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-05-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240091213-A1 COMPOUNDS FOR TAU PROTEIN DEGRADATION UBQLN1, UBQLN2, CRBN GABRG2 1963/4885GABRB3 1765/4885GABRA5 2021/4885
US-12622901-B2 Compounds for tau protein degradation MAPT, UBQLN1, PSEN1 GABRG2 2087/4885GABRB3 1829/4885GABRA5 1539/4885
US-20210154184-A1 COMPOUNDS FOR TAU PROTEIN DEGRADATION UBQLN1, UBQLN2, CRBN GABRG2 1963/4885GABRB3 1765/4885GABRA5 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback